Excellent results were seen when 100 patients with ankylosing spondylitis who had undergone total replacement arthroplasty of the hip were reviewed 5 years after operation. One hundred and sixty hips had been replaced; 92.5% were painfree, 78% had flexion of greater than 90 degrees and 80% walked well without a stick. Using the scale of Merle d'Aubigné and Postel, 86% of the results were classed as satisfactory. The Muller and Charnley prostheses were very reliable. The outcome in hips with marked degenerative or hypertrophic changes were better than in those which were ankylosed. Operation is best carried out early before the joints are grossly damaged.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00266376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy.
Dokl Biochem Biophys
August 2024
Nasonova Research Institute of Rheumatology, Moscow, Russia.
Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS.
View Article and Find Full Text PDFRecommendations of the Moroccan Society of Rheumatology (SMR) for Diagnostic Management of Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA).
Mediterr J Rheumatol
September 2023
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco.
In 2017, the Moroccan Society of Rheumatology (SMR) issued guidelines for the treatment of severe ankylosing spondylitis. The emergence of new therapeutic classes, the update of international guidelines for axial SpA and psoriatic arthritis, and the diagnostic and therapeutic challenges encountered by rheumatologists has led to the development of recent SMR guidelines for the management of SpA patients. A group-work included rheumatologists, specialists in physical medicine and rehabilitation, and epidemiologists from various sectors was tasked with writing these recommendations based on a literature review, then adapting them to the national context.
View Article and Find Full Text PDFImprovement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitor golimumab: Results of a 24-Month prospective observation study (GO-COX Study).
Int J Rheum Dis
July 2023
MSD Pharmaceuticals LLC, Moscow, Russia.
Aim: The hip joint is the most commonly affected non-axial joint in ankylosing spondylitis (AS). Data on the effects of tumor necrosis factor-α inhibitors (TNFi) in AS patients with coxitis are limited. The aim of this study was evaluation of coxitis treated with the TNFi golimumab in real-world settings.
View Article and Find Full Text PDFImmunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis.
Drug Metab Pers Ther
November 2020
Doctor in the Department of Rheumatology, Charles Nicolle Hospital, Tunis, Tunisia.
Objectives To evaluate the serum dosage of the biomedicine (DBM) and the incidence of antidrug antibody (ADA) against antitumor necrosis factor (TNF) in spondyloarthritis, and to demonstrate the influence of these parameters on the clinical efficiency. Methods We conducted a cross-sectional multicentric study including patients with spondylarthritis (SpA) under antiTNF (infliximab [INF], etanercept [ETA] and adalimumab [ADL]) for at least 6 months. A dosage of the ADA and DBM were practiced by the immuno-enzymatic essay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!